Patents by Inventor Christopher R. COGLE
Christopher R. COGLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230092232Abstract: Provided herein are compositions and methods for eliciting a desired immune response in a subject in need thereof. The compositions and methods are particularly useful as anti-cancer immune therapy by exploiting a subject's propensity for drug (e.g small molecule) hypersensitivity. Of particular significance is the application in personalized immune therapy for cancer patients utilizing or repurposing existing FDA approved drugs.Type: ApplicationFiled: February 26, 2021Publication date: March 23, 2023Applicant: University of Florida Research Foundation, IncorporatedInventors: David A. Ostrov, Christopher R. Cogle
-
Patent number: 11014876Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.Type: GrantFiled: November 4, 2016Date of Patent: May 25, 2021Assignees: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular StudiesInventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
-
Patent number: 10322149Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.Type: GrantFiled: August 14, 2017Date of Patent: June 18, 2019Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
-
Publication number: 20180297942Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.Type: ApplicationFiled: November 4, 2016Publication date: October 18, 2018Applicants: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular StudiesInventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
-
Publication number: 20180064760Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.Type: ApplicationFiled: August 14, 2017Publication date: March 8, 2018Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
-
Patent number: 9730960Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.Type: GrantFiled: June 11, 2012Date of Patent: August 15, 2017Assignee: University of Florida Research Foundation, Inc.Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
-
Publication number: 20140328804Abstract: A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject.Type: ApplicationFiled: June 11, 2012Publication date: November 6, 2014Applicant: University of Florida Research Foundation, Inc.Inventors: Douglas G. McFadden, Eric C. Bartee, Christopher R. Cogle
-
Publication number: 20110280874Abstract: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.Type: ApplicationFiled: January 22, 2010Publication date: November 17, 2011Inventors: Edward W. Scott, Christopher R. Cogle
-
Publication number: 20090291087Abstract: Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can be increased or decreased. The present invention features compositions and methods for reducing tumor vasculogenesis, treating leukemia, and/or treating or preventing leukemia relapse. In particular, the invention provides an SDF-1 binding agent (e.g., antibody, antisense, ribozyme) for the treatment or prevention of a neoplasia, such as leukemia. Intravitreal injection of antibodies that block SDF-1 activity inhibited induced retinal neovascularization mediated by hemangioblasts. Anti-SDF-1 ribozymes and SDF-1 anti-sense RNA expression constructs significantly reduced migration of cells that create new vessels in the eye.Type: ApplicationFiled: January 23, 2009Publication date: November 26, 2009Applicant: University of Florida Research Foundation, Inc.Inventors: Edward W. SCOTT, Christopher R. COGLE